PT2933251T - Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado - Google Patents

Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado

Info

Publication number
PT2933251T
PT2933251T PT151634540T PT15163454T PT2933251T PT 2933251 T PT2933251 T PT 2933251T PT 151634540 T PT151634540 T PT 151634540T PT 15163454 T PT15163454 T PT 15163454T PT 2933251 T PT2933251 T PT 2933251T
Authority
PT
Portugal
Prior art keywords
pathology
foot
treatment
pharmaceutical composition
composition usable
Prior art date
Application number
PT151634540T
Other languages
English (en)
Original Assignee
Peter Weyts
Celine Bourgeois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Weyts, Celine Bourgeois filed Critical Peter Weyts
Publication of PT2933251T publication Critical patent/PT2933251T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT151634540T 2014-04-15 2015-04-14 Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado PT2933251T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1453382A FR3019820B1 (fr) 2014-04-15 2014-04-15 Composes de type flavonoides pour leur utilisation dans le traitement d'une pathologie du pied d'un mammifere ongule-composition pharmaceutique associee

Publications (1)

Publication Number Publication Date
PT2933251T true PT2933251T (pt) 2021-08-13

Family

ID=51483548

Family Applications (1)

Application Number Title Priority Date Filing Date
PT151634540T PT2933251T (pt) 2014-04-15 2015-04-14 Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado

Country Status (5)

Country Link
EP (1) EP2933251B1 (pt)
ES (1) ES2881547T3 (pt)
FR (1) FR3019820B1 (pt)
MA (1) MA38619A (pt)
PT (1) PT2933251T (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710844B1 (fr) * 1993-10-07 1995-12-29 Bidel Christian Georges Composition pour le traitement ou la prévention de l'herpès.
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
PL380446A1 (pl) * 2003-12-18 2007-02-05 Nestec S.A. Kompozycja zawierająca flawanony do polepszania stanu zdrowia skóry, włosów lub sierści i futra
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
CA2615444A1 (en) * 2005-07-15 2007-01-25 Donald J. Baker Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals
ITMI20052461A1 (it) * 2005-12-22 2007-06-23 Univ Degli Studi Milano Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive
DE502007002101D1 (de) * 2007-03-12 2010-01-07 Dobavet Gmbh Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
MX2007011002A (es) * 2007-09-07 2009-03-09 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de diversos agentes venotonicos y vasoprotectores para el tratamiento de la insuficiencia venosa cronica.
US8557275B2 (en) * 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
EP2353596A1 (en) * 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
FI20106119A0 (fi) * 2010-10-27 2010-10-27 Sirtuin Valley Oy Energia-aineenvaihduntaan vaikuttava koostumus

Also Published As

Publication number Publication date
EP2933251A1 (fr) 2015-10-21
FR3019820B1 (fr) 2017-07-21
ES2881547T3 (es) 2021-11-29
FR3019820A1 (fr) 2015-10-16
MA38619A (fr) 2021-06-02
EP2933251B1 (fr) 2021-07-07

Similar Documents

Publication Publication Date Title
HK1251257A1 (zh) 用於醫治疾病的外泌體的用途
IL270954A (en) Pharmaceutical compounds
IL253945A0 (en) kdm1a inhibitors to treat the disease
GB201404922D0 (en) Pharmaceutical compounds
HK1244485A1 (zh) 用於治療神經母細胞瘤的組合物
GB201415569D0 (en) Therapeutic Compounds
GB201410816D0 (en) Therapeutic agents
GB201416513D0 (en) Pharmaceutical compounds
IL248779A0 (en) Pharmaceutical preparations for the treatment of infectious diseases
GB201410817D0 (en) Therapeutic agents
GB201410815D0 (en) Therapeutic agents
GB201417707D0 (en) Pharmaceutical compounds
GB201416273D0 (en) Therapeutic compounds
PL3142641T3 (pl) Preparaty do leczenia nadczynności tarczycy
SG11201608123VA (en) Pharmaceutical composition for external use
GB201417589D0 (en) Pharmaceutical Formulations
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
SG11201608124XA (en) Pharmaceutical composition for external use
PT2933251T (pt) Composição farmacêutica que pode ser utilizada para o tratamento de uma patologia do pé de um mamífero ungulado
SG11201608122PA (en) Pharmaceutical composition for external use
GB201508022D0 (en) Pharmaceutical compounds
FR3024036B1 (fr) Composes volatils pour le traitement du neuropaludisme
GB201421879D0 (en) Therapeutic agents
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds